

"Finally, we observe that it might indeed be difficult to find a diabetic who would act as a guinea-pig by abandoning insulin over any substantial period of time and submitting to treatment by 'Diabena' or any other drug whose efficiency has not been established. Diabetes is a serious disease which, if not properly and promptly treated, tends to become increasingly dangerous. Indeed, Dr. Tucker unhesitatingly testified that if a person suffering from diabetes is deprived of insulin, serious consequences might well follow.

"We think the Government has clearly established its case by a preponderance of the evidence. The judgment of the District Court is, accordingly, reversed and the case is remanded to that court with instructions to enter judgment in favor of the United States."

The case was remanded to the United States District Court for the Eastern District of Virginia; and, on 3-22-56, the court ordered the product destroyed.

**4794. Reclu capsules.** (F. D. C. No. 37111. S. No. 40-270 L.)

QUANTITY: 12 100-capsule btls. at Phoenix, Ariz.

SHIPPED: 7-28-54 and 9-4-54, from Fullerton, Calif., by Reclu Co.

LABEL IN PART: (Btl.) "Reclu Caps Each Capsule Contains Approx. 0.58 Grams Of A Specially Prepared Concentrate Made From Fresh Cabbage, Desiccated At Low Temp. \* \* \* Reclu's Cabbage Concentrate Diet for Peptic Ulcers."

LIBELED: 9-30-54, Dist. Ariz.

CHARGE: 502 (a)—the bottle label of the article when shipped contained false and misleading representations that the article was an adequate and effective treatment for peptic ulcers.

DISPOSITION: 11-24-54. Default—destruction.

**4795. Trumac tablets.** (F. D. C. No. 36865. S. No. 90-431 L.)

QUANTITY: 10 cases, 12 btls. each, at Kansas City, Kans.

SHIPPED: 5-11-54, from Detroit, Mich., by Cemac Laboratories, Inc.

LABEL IN PART: (Btl.) "100 Tablets Trumac Tablets Enteric Coated Improved For the palliative relief of pain (headache) associated with Sinus Conditions, Facial Neuralgia, and Simple Headache. Contains: Salicylamide, as the active ingredient; with a catalytic agent CS 210 in a specially prepared base."

ACCOMPANYING LABELING: A flier designated "SINUS? . . . get palliative relief with TRUMAC TABLETS"; a leaflet designated "Are You A SINUS Victim?"; and placards designated "Are You a Sinus Victim? Ask About The New Tablet Treatment TRUMAC TABLETS"; and "TRUMAC TABLETS For the Palliative Relief of Pain Associated with Sinus Conditions."

LIBELED: 7-8-54, Dist. Kans.

CHARGE: 502 (a)—when the article was shipped, its bottle label and accompanying labeling contained false and misleading representations that the article was an adequate and effective treatment for sinus conditions.

DISPOSITION: 10-12-54. Default—destruction.

**4796. Artritina tablets.** (F. D. C. No. 37298. S. No. 40-268 L.)

QUANTITY: 48 100-tablet btls. at Phoenix, Ariz.

SHIPPED: 2-11-54, from Los Angeles, Calif., by Los Angeles Pharmacal Co.

**LABEL IN PART:** (Btl.) "Artritina For the relief of symptoms of Arthritis, Rheumatism & Neuritis Each tablet contains: Salicylamide. . . . 3.0 grs. Calcium Succinate. . . . 2.8 grs. Thiamine Chloride. . . . 1.0 mg. Para Aminobenzoic Acid. . . . 10.0 mg."

**LIBELED:** 10-22-54, Dist. Ariz.

**CHARGE:** 502 (a)—the label of the article when shipped contained false and misleading representations that the article was an adequate and effective treatment for arthritis, rheumatism, and neuritis, and that it was effective for overcoming all of the symptoms and signs of such conditions.

**DISPOSITION:** 2-14-55. Default—destruction.

**4797. Anterior pituitary extract and ovarian extract.** (F. D. C. No. 37591. S. Nos. 8-500/1 L.)

**QUANTITY:** 24 30-cc. vials of *anterior pituitary extract* and 30 30-cc. vials of *ovarian extract* at Syracuse, N. Y.

**SHIPPED:** 10-20-53 and 12-11-53, from Philadelphia, Pa., by Addison Laboratories.

**LABEL IN PART:** (Vial) "Multiple Dose Vial Anterior Pituitary Extract Each cc. contains the soluble water extract of 18.5 grains of fresh anterior pituitary glands. Intramuscularly or Subcutaneously \* \* \* in severe functional hemorrhage," and "Multiple-Dose Vial Ovarian Extract \* \* \* Intramuscular \* \* \* Each cc. contains: Ovarian Extract 40 gr. Chlorobutanol 0.5% \* \* \* in the treatment of functional menstrual irregularities, climacteric symptoms and related conditions."

**LIBELED:** 1-11-55, N. Dist. N. Y.

**CHARGE:** 502 (a)—the labels of the articles contained false and misleading representations that the *anterior pituitary extract* was effective in the treatment of functional hemorrhage and that the *ovarian extract* was effective in the treatment of functional menstrual irregularities, climacteric symptoms, and related conditions.

**DISPOSITION:** 3-2-55. Default—destruction.

**4798. Glanfime.** (F. D. C. No. 37043. S. No. 58-694 L.)

**QUANTITY:** 317 cartoned vials at Detroit, Mich.

**SHIPPED:** 2-12-54, from Philadelphia, Pa., by Vitamix Corp.

**LABEL IN PART:** (Vial) "30 cc. \* \* \* Glanfime Intramuscular Only \* \* \* Indications: Non-Specific Protein Therapy. To be used as an appetite depressant in the treatment of obesity."

**LIBELED:** 8-10-54, E. Dist. Mich.

**CHARGE:** 502 (a)—the statement on the vial label of the article when shipped "Indications: Non-Specific Protein Therapy" was false and misleading since the statement represented and suggested that the article was effective, upon injection, to cause a foreign protein reaction, which was contrary to fact; and 502 (a)—the name "Glanfime" and the statements on the vial label "Each 2 cc. represents the water soluble extraction of dried glands derived from: \* \* \* Suprarenal Cortex, fresh gland ---- 3.0 grs. Thyroid U. S. P. ---- 2.0 grs. Pituitary Anterior, fresh gland ---- 1.0 grs. Pituitary Posterior, fresh gland ---- 0.1 grs. Ovarian Substance, fresh gland ---- 15.0 grs. Thymus, fresh gland ---- 3.0 grs. Lymphatic, fresh gland ---- 3.0 grs." were false and misleading since such name and statements represented and suggested that the declared glandular extracts